113 results
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
24 Jun 24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
7:46am
inherent in research and development; our dependence on third-party suppliers; government regulation; patent and intellectual property matters
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
10 May 24
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
8:45am
equivalents totaled $11.2 million, compared to $4.9 million at December 31, 2023, an increase of $6.3 million.
R&D Expenses: Research and development … for substantial additional funds; other uncertainties inherent in research and development; our dependence on third-party suppliers; government regulation
8-K
EX-99.1
lxfyyupsefo
22 Mar 24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
8:52am
8-K
EX-99.1
z9k0q5ij f8ejuk9j
18 Mar 24
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
4:05pm
424B5
u53s8i6vgtnv y05z2e
30 Jan 24
Prospectus supplement for primary offering
5:10pm
8-K
EX-99.1
z52p63ptkfqdsbkj 4mo
30 Jan 24
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
5:00pm
8-K
EX-99.1
ml6f66un 7m5zyjn1vlf
18 Dec 23
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
7:10am
8-K
EX-99.1
0yo0k
13 Nov 23
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
5:10pm
8-K
EX-99.1
26xu9r0uqfhhji57sj
3 Oct 23
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
5:00pm
8-K
EX-99.1
5kf hhkl091f8tkh0
14 Aug 23
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:30pm
8-K
EX-99.1
7ffnlgpe9r dgc99g91y
31 Jul 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
8:28am
424B5
bt3ku4fred18 16cei
31 Jul 23
Prospectus supplement for primary offering
8:23am